FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma

Trial

CLEAR

Drugs

Lenvima (lenvatinib) · Multikinase inhibitor, Keytruda (pembrolizumab) · Anti-PD-1 antibody

Condition

Genitourinary